StockNews.AI
CRVS
StockNews.AI
118 days

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

1. Corvus Pharmaceuticals presents trial data for soquelitinib at SID 2025. 2. New Phase 1 data demonstrates efficacy in treating atopic dermatitis. 3. The financial results call will provide further updates on May 8, 2025. 4. Soquelitinib is targeting immune diseases and cancer with novel mechanisms. 5. Presentation at SID 2025 could influence investor sentiment positively.

5m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial data can lead to increased investor interest, similar to past successes like Amgen's psoriasis drug results.

How important is it?

The new data from a Phase 1 trial presents a significant development for CRVS, likely influencing both market confidence and stock price. Investors typically react favorably to promising clinical trial outcomes.

Why Short Term?

Upcoming presentations and financial results could generate immediate market reactions, akin to initial drug trial announcements.

Related Companies

AMGNVRTXINCY
April 23, 2025 16:08 ET  | Source: Corvus Pharmaceuticals, Inc. Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA. Presentation details are as follows: Title: Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of actionAbstract #: 0437Presenter: Albert S. Chiou, M.D., MBA, Clinical Associate Professor, Dermatology and Director of Clinical Research in the Department of Dermatology at Stanford University Medical CenterPoster Presentation Date and Time: May 8, 2025 from 4:30 – 6:00 pm PTOral Presentation Date and Time: May 10, 2025 from 9:50 – 10:00 am PT First Quarter 2025 Financial Results Conference Call and WebcastCorvus will present details on the new data from the soquelitinib Phase 1 clinical trial during the Company’s first quarter 2025 business update conference call and webcast, which is scheduled for Thursday, May 8, 2025 at 4:30 pm ET / 1:30 pm PT. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com

Related News